Document Type : Original Article
Department of General Surgery, Zhejiang Greentown Cardiovascular Hospital, Hangzhou, Zhejiang, China
Department of Emergency, Zhejiang Greentown Cardiovascular Hospital, Hangzhou, Zhejiang, China
Department of Dermatology, The Second People's Hospital of Yuhang District, Hangzhou, Zhejiang, China
Objective: Cordycepin, also known as 3ˊ-deoxyadenosine, is the main bioactive ingredient of Cordyceps militaris and possesses various pharmacological effects. This study was performed to investigate the role of cordycepin in regulating the biological behaviors of colon cancer cells and the potential mechanism behind it.
Materials and Methods: In this experimental study, after treatment of colon cancer cells with different concentrations of cordycepin, inhibition of proliferation was detected by the 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Colon cancer cell migration and invasion abilities were analyzed by wound healing and Transwell assays. Flow cytometry was performed to detect cell apoptosis. A lung metastasis model in nude mice was utilized to examine the effect of cordycepin on the metastasis of colon cancer cells in vivo. Western blot was used to quantify GSK3β, β-catenin and cyclin D1 expression levels.
Results: Cordycepin inhibited colon cancer cell proliferation, migration and invasion, induced apoptosis in vitro, and inhibited lung metastasis of colon cancer cells in vivo. GSK-3β inhibitor (CHIR99021) treatment abolished the effects of cordycepin on cell viability, migration, invasion and apoptosis. Additionally, cordycepin promoted the expressions of GSK3β, and inhibited β-catenin and cyclin D1 in colon cancer cells, while co-treatment with CHIR99021 reversed the above effects.
Conclusion: Cordycepin suppresses the malignant phenotypes of colon cancer through the GSK3β/β-catenin/cyclin D1 signaling pathway.